Loading...
Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
BACKGROUND: Low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice. HYPOTHESIS: We assessed LDL‐C lowering during 1 year of evolocumab ther...
Na minha lista:
| Udgivet i: | Clin Cardiol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wiley Periodicals, Inc.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8119857/ https://ncbi.nlm.nih.gov/pubmed/33760276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23600 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|